Acasti Pharma appoints Robert J. DelAversano as principal financial and accounting officer, effective Jan 5, 2024

Grace Therapeutics, Inc.

Robert J. DelAversano, 52, CPA and former VP Finance, becomes principal financial and accounting officer.
Brian Ford removed as interim-CFO; remains as financial consultant on an as-needed basis.
DelAversano receives $290,000 base salary, up to 30% target bonus, and 42,000 stock options at $2.125 per share.
DelAversano joined Acasti in Nov 2023; prior experience at OncoSec and Brio Financial Group.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brian Ford

Interim Chief Financial Officer

GRCE · Grace Therapeutics, Inc.

Effective: 2024-01-05
Successor: Robert J. DelAversano
Filed: January 8, 2024, 6:59 PM ET

Concurrently with such appointment, the Board removed Brian Ford from the position of interim-Chief Financial Officer.

Appointed

Robert J. DelAversano

Principal Financial Officer and Principal Accounting Officer

GRCE · Grace Therapeutics, Inc.

Effective: 2024-01-05
Successor: Brian Ford
Filed: January 8, 2024, 6:59 PM ET

On January 5, 2024, the Board of Directors (the “Board”) of Acasti Pharma Inc. (the “Company”) approved the appointment of Robert J. DelAversano, the Company's Vice President, Finance, to the roles of principal financial officer and principal accounting officer of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Ford was removed as Interim Chief Financial Officer at Grace Therapeutics, Inc..

Action: removed
Role: Interim Chief Financial Officer

Exact text from the filing

Concurrently with such appointment, the Board removed Brian Ford from the position of interim-Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert J. DelAversano was appointed as Principal Financial Officer and Principal Accounting Officer at Grace Therapeutics, Inc..

Action: appointed
Role: Principal Financial Officer and Principal Accounting Officer

Exact text from the filing

On January 5, 2024, the Board of Directors (the “Board”) of Acasti Pharma Inc. (the “Company”) approved the appointment of Robert J. DelAversano, the Company's Vice President, Finance, to the roles of principal financial officer and principal accounting officer of the Company, effective immediately.

View on SEC.gov

Grace Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-002689

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.